Tg Therapeutics annual operating margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tg Therapeutics's operating margin was 20.01% for fiscal 2025.
View full Tg Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 20.01% | +7.27 pp |
| 2024 | 2024-12-31 | 12.74% | +3.91 pp |
| 2023 | 2023-12-31 | 8.83% | +7847.82 pp |
| 2022 | 2022-12-31 | −7,838.99% | −2684.71 pp |
| 2021 | 2021-12-31 | −5,154.28% | +174841.77 pp |
| 2020 | 2020-12-31 | −179,996.05% | −68775.66 pp |
| 2019 | 2019-12-31 | −111,220.39% | +3516.45 pp |
| 2018 | 2018-12-31 | −114,736.84% | −36636.84 pp |
| 2017 | 2017-12-31 | −78,100.00% | −26146.71 pp |
| 2016 | 2016-12-31 | −51,953.29% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.02% | −15.67 pp |
| Q1 2026 | 2026-03-31 | 16.98% | +9.85 pp |
| Q4 2025 | 2025-12-31 | 26.22% | −1.46 pp |
| Q3 2025 | 2025-09-30 | 18.16% | +3.34 pp |
| Q2 2025 | 2025-06-30 | 24.69% | +12.69 pp |
| Q1 2025 | 2025-03-31 | 7.13% | +21.74 pp |
| Q4 2024 | 2024-12-31 | 27.68% | +56.08 pp |
| Q3 2024 | 2024-09-30 | 14.82% | −54.40 pp |
| Q2 2024 | 2024-06-30 | 12.00% | +289.93 pp |
| Q1 2024 | 2024-03-31 | −14.60% | +459.47 pp |
| Q4 2023 | 2023-12-31 | −28.39% | +95700.00 pp |
| Q3 2023 | 2023-09-30 | 69.22% | +37263.90 pp |
| Q2 2023 | 2023-06-30 | −277.93% | +6277.80 pp |
| Q1 2023 | 2023-03-31 | −474.07% | +2842.99 pp |
| Q4 2022 | 2022-12-31 | −95,728.40% | −91723.74 pp |
| Q3 2022 | 2022-09-30 | −37,194.68% | −33001.18 pp |
| Q2 2022 | 2022-06-30 | −6,555.72% | −1540.06 pp |
| Q1 2022 | 2022-03-31 | −3,317.06% | +7931.61 pp |
| Q4 2021 | 2021-12-31 | −4,004.65% | +224369.03 pp |
| Q3 2021 | 2021-09-30 | −4,193.50% | +221390.71 pp |
| Q2 2021 | 2021-06-30 | −5,015.66% | +128786.97 pp |
| Q1 2021 | 2021-03-31 | −11,248.68% | +120975.01 pp |
| Q4 2020 | 2020-12-31 | −228,373.68% | −128476.32 pp |
| Q3 2020 | 2020-09-30 | −225,584.21% | −65423.68 pp |
| Q2 2020 | 2020-06-30 | −133,802.63% | −40265.79 pp |
| Q1 2020 | 2020-03-31 | −132,223.68% | −40936.84 pp |
| Q4 2019 | 2019-12-31 | −99,897.37% | +275997.37 pp |
| Q3 2019 | 2019-09-30 | −160,160.53% | −69823.68 pp |
| Q2 2019 | 2019-06-30 | −93,536.84% | −210234.21 pp |
| Q1 2019 | 2019-03-31 | −91,286.84% | +18126.32 pp |
| Q4 2018 | 2018-12-31 | −375,894.74% | −292776.32 pp |
| Q3 2018 | 2018-09-30 | −90,336.84% | −15534.21 pp |
| Q2 2018 | 2018-06-30 | 116,697.37% | — |
| Q1 2018 | 2018-03-31 | −109,413.16% | — |
| Q3 2017 | 2017-09-30 | −83,118.42% | — |
| Q2 2017 | 2017-06-30 | −74,802.63% | — |
Over the last five reported fiscal years, Tg Therapeutics's operating margin increased from −179,996.05% to 20.01%, a change of +180016.06 percentage points. The latest reported quarter, Q2 2026, shows 9.02%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tg Therapeutics filings at SEC.gov ↗